Literature DB >> 10873872

Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease.

S A Grampsas1, P S Chandhoke, J Fan, M A Glass, R Townsend, A M Johnson, P Gabow.   

Abstract

The prevalence of nephrolithiasis is considerably greater in patients with autosomal dominant polycystic kidney disease (ADPKD) than in the general population. We evaluated anatomic and metabolic factors that may be associated with an increased prevalence of nephrolithiasis in patients with ADPKD. We compared anatomic parameters among ADPKD patients with or without nephrolithiasis as diagnosed by ultrasonography, whereas metabolic factors were determined by 24-hour urinary chemical analysis. Patients with ADPKD and nephrolithiasis had more renal cysts (P < 0.05) and a larger predominant renal cyst size (P < 0.005) than patients without nephrolithiasis. Concurrently, individual stone-forming kidneys had a greater cyst number (P < 0.05) and a significantly larger predominant cyst size (P < 0.01) compared with kidneys without stones. Patients with ADPKD and nephrolithiasis had a significantly lower creatinine clearance than those without nephrolithiasis (68.7 +/- 8.6 versus 94.8 +/- 5.4 mL/min, respectively; P < 0.05). Twenty-four-hour urinary analysis showed that patients with ADPKD and nephrolithiasis had significantly lower urinary volumes (P < 0. 05), and levels of urinary phosphate (P < 0.05), magnesium (P < 0. 005), and potassium (P < 0.05). Although not statistically significant, patients with ADPKD with stones tended to have lower levels of urinary citrate, and both groups showed a high percentage (range, 49% to 60%) of patients with hypocitraturia. Our data are consistent with the hypothesis that patients with ADPKD who develop nephrolithiasis do so because of increased intrarenal anatomic obstruction, as well as lower levels of such urinary inhibitors of stones as magnesium and citrate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873872     DOI: 10.1053/ajkd.2000.8266

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  28 in total

1.  Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

Authors:  Matteo Bargagli; Nasser A Dhayat; Manuel Anderegg; Mariam Semmo; Uyen Huynh-Do; Bruno Vogt; Pietro Manuel Ferraro; Daniel G Fuster
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

2.  Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Authors:  Connie J Wang; Catherine Creed; Franz T Winklhofer; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

3.  Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Authors:  Jacob A Torres; Mina Rezaei; Caroline Broderick; Louis Lin; Xiaofang Wang; Bernd Hoppe; Benjamin D Cowley; Vincenzo Savica; Vicente E Torres; Saeed Khan; Ross P Holmes; Michal Mrug; Thomas Weimbs
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

Review 4.  Lithiasis in cystic kidney disease and malformations of the urinary tract.

Authors:  G Gambaro; A Fabris; D Puliatta; A Lupo
Journal:  Urol Res       Date:  2006-01-14

Review 5.  Evaluation and management of pain in autosomal dominant polycystic kidney disease.

Authors:  Marie C Hogan; Suzanne M Norby
Journal:  Adv Chronic Kidney Dis       Date:  2010-05       Impact factor: 3.620

Review 6.  Stones in special situations.

Authors:  Mordechai Duvdevani; Stavros Sfoungaristos; Karim Bensalah; Benoit Peyronnet; Amy Krambeck; Sanjay Khadji; Ahmet Muslumanuglu; David Leavitt; Jude Divers; Zeph Okeke; Arthur Smith; Janelle Fox; Michael Ost; Andreas J Gross; Hassan Razvi
Journal:  World J Urol       Date:  2017-03-07       Impact factor: 4.226

7.  Flexible ureteroscopy and holmium laser lithotripsy for treatment of upper urinary tract calculi in patients with autosomal dominant polycystic kidney disease.

Authors:  Liu Yili; Li Yongzhi; Li Ning; Xue Dongwei; Liu Chunlai; Liu Suomin; Wang Ping
Journal:  Urol Res       Date:  2011-05-25

8.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

9.  Percutaneous nephrolithotomy in polycystic kidney disease: is it safe and effective?

Authors:  Aneesh Srivastava; Rajesh Bansal; Alok Srivastava; Samit Chaturvedi; Priyadarshi Ranjan; M S Ansari; Abhishek Yadav; Rakesh Kapoor
Journal:  Int Urol Nephrol       Date:  2011-11-20       Impact factor: 2.370

10.  Determination of urinary lithogenic parameters in murine models orthologous to autosomal dominant polycystic kidney disease.

Authors:  Renato Ribeiro Nogueira Ferraz; Jonathan Mackowiak Fonseca; Gregory George Germino; Luiz Fernando Onuchic; Ita Pfeferman Heilberg
Journal:  Urolithiasis       Date:  2014-05-10       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.